sutthirat sutthisumdang UBS initiated coverage of Telix Pharmaceuticals ( NASDAQ: TLX ) American depositary shares with a buy rating, citing upcoming catalysts. The bank said it currently sees the Australian company’s only marketed product, Illuccix, a PSMA-targeted PET scanning agent for metastatic castrate resistant prostate cancer, as having.
Back to Health Page
